Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 572-skin-debridement-without-cc-mcc
    Ask Trek AI about this page

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    DRG 572 includes inpatient skin debridement procedures without Complications or Comorbidities or Major Complications or Comorbidities, focusing on uncomplicated removal of necrotic or infected tissue. It matters for inpatient reimbursement because it defines the bundled Medicare payment for stays with lower expected resource utilization.

    Customize your policy alerts

    Sign up for drg 572 policy alerts

    Get alerted when payer policies referencing 572 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 572 Overview

    DRG 572 covers inpatient stays involving skin debridement procedures when there are no Complications or Comorbidities and no Major Complication or Comorbidity present. Typical cases include surgical removal of necrotic or infected skin and soft tissue without other significant diagnoses that would increase resource use. This Diagnosis-Related Group matters for Medicare payment because it establishes the bundled payment amount for these straightforward debridement admissions. Correct coding and documentation determine assignment to this group and the associated inpatient reimbursement level.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute procedural optimization studies: randomized or prospective trials comparing different operative and non-operative debridement techniques (sharp surgical debridement, hydrosurgical debridement, enzymatic debridement, or pulse lavage) performed in the inpatient setting for patients with extensive necrotic wounds, pressure ulcers, or complicated lacerations. These studies enroll patients at the time of admission who require immediate wound bed preparation and aim to measure time to viable granulation tissue, need for repeat debridement, infection control, and short-term resource utilization (operating room time, antibiotic days, and length of stay). Results inform clinicians about procedural efficacy and safety and help payers project costs and appropriate bundling of inpatient debridement services under this DRG.
    • Comparative effectiveness trials of adjunctive wound therapies combined with debridement: pragmatic studies that compare outcomes when standard inpatient debridement is followed by different adjuncts such as advanced dressings, negative pressure wound therapy, or biologic wound matrices in subgroups like diabetic foot wounds, venous stasis ulcers with cellulitis, or traumatic soft-tissue defects. These trials focus on healing rates, reoperation or readmission within 30 days, and total inpatient-to-post-discharge care costs, enrolling patients after initial debridement to evaluate which adjuncts reduce complications and accelerate recovery. Findings are directly relevant to providers choosing post-debridement pathways and to payers interested in interventions that reduce downstream utilization and readmissions within the DRG population.
    • Post-discharge outcomes and care-transition studies: cohort or interventional studies assessing the impact of discharge planning, early outpatient wound clinic follow-up, home health nursing, or telemedicine wound monitoring on readmission rates, wound healing trajectory, and total episode-of-care costs for patients discharged after inpatient debridement (often older adults, those with mobility limitations, or patients with comorbid diabetes or peripheral vascular disease). These studies track 30- and 90-day outcomes, patient adherence to wound care, and emergency department visits to identify high-risk subgroups and effective transitional care models. Results guide hospital quality improvement, reduce preventable readmissions that affect reimbursement, and inform payers about care coordination investments that can lower overall expenditures for this DRG.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.